China Boosts Global Innovative Drug Pipeline Post-2016 Reforms

The long-standing hierarchy of global pharmaceutical innovation — with the United States at the top, Europe and Japan in a strong second tier, and developing countries as free riders producing generics — is undergoing a fundamental shift. New research presented by Hong Yuan (Cornell University),  systematically documents China’s transition from a pharmaceutical follower to an active contributor to the global innovative drug pipeline.

At [2:17:09–2:17:41], Yuan framed the established narrative:

“Since the Second World War, the policies and economics literatures have largely taken for granted a very clear hierarchy of pharmaceutical innovation. In that hierarchy, US sits at the top as a leader. It produces way more innovative drugs than any other countries. … But developing countries, they are mostly free riders. They consume innovation. They produce generics, but they’re never expected to contribute to the global pipeline of innovative drugs.”

Ad

The paper presented by Yuan assembles comprehensive data spanning 2010–2024 across clinical trials, patents, drug sales, publications, venture capital investments, and policy records to answer three research questions: (1) can a developing country like China genuinely transition from receiver to contributor of biomedical innovation; (2) if real, what drove this transition — economic growth or deliberate policy reform; and (3) what are the welfare implications for patients in China and globally.

The Evidence: China’s Entry into the Global Innovative Drug Pipeline

The study documents a sharp structural break around 2016. Before that year, clinical trial activity in China tracked largely parallel to the United States and Europe. After 2016, China experienced a steep acceleration [2:26:55–2:27:20]:

“Before 2016, the clinical trial activity in China is largely parallel to that of the US or Europe. But after 2016, the trial activity in China experienced a sharp surge. And around 2020, China has surpassed the US and produced more clinical trials. This trend continues and in 2024, China produced 1,500 more clinical trials than that of the US.”

The growth is not merely in early-stage R&D efforts. Two milestone events — out-licensing to international firms and global first approvals — show the same pattern. Before 2016, licensed-out drugs from Chinese firms were near zero; by 2024 they reached roughly one-third of US levels. First approvals by Chinese firms surpassed those by US firms in 2024.

Not Just Quantity: Three Measures of Novelty

A common counterargument is that China’s trial growth reflects copycat or me-too drugs rather than genuine innovation. The paper addresses this with three novelty measures:

1. Target-based novelty: trials exploring infrequently studied biological mechanisms or targets
2. Non-generic trials only: excluding all trials investigating new targets, indications, molecules, or combinations
3. Phase 3 trials with innovative comparators: trials where the control arm is an innovative drug rather than a placebo or generic

All three measures show consistent results. Novel trials increased 123% in 2024 compared to 2015, relative to the US. First-in-class drugs show similar pattern.

Importantly, only 2.5% of trials are conducted in both China and the US — ruling out the concern that the surge merely reflects multinational reallocation of trial sites. The increase is driven predominantly by China-headquartered firms, whose trials increased 200%, while trials by international firms in China grew modestl.

Why Did This Happen? The NRDL Reform as Primary Driver

The paper examines both demand-side and supply-side mechanisms. The National Reimbursement Drug List (NRDL) reform emerges as the dominant factor, explaining 59% of oncology trial growth.

Before 2016, China’s public insurance formulary prioritised generic drug coverage, largely excluding innovative therapies. Approved innovative drugs remained on the private market with severely limited patient access. The reform introduced centralised annual negotiation rounds that selectively favour innovative drugs: firms accept significant price reductions in exchange for insurance coverage and access to China’s vast patient populatio.

This creates a classic price–quantity trade-off. The paper’s staggered difference-in-differences analysis shows that NRDL inclusion reduces drug prices by 50–60%, while revenue doubles on average — and increases up to 500% for oncology drug.

Other Mechanisms: Knowledge, Talent, and Capital

Knowledge accumulation and talent flow each explain roughly 20% of trial growth. China’s biomedical publication output and the number of scientists with US experience returning to China have both increased steadily — but without a trend break around 2016, so they cannot explain the sudden surge.

Venture capital investment also explains approximately 20%, but VC activity declined significantly after 2021 due to global capital market shifts, while clinical trial growth continue.

Other factors examined — including the 2015 application backlog reform (which reduced IND review times from over a year to 1–2 months) and the 2017 ICH harmonization — had relatively modest effects in the decomposition analysis.

Welfare Implications: Innovation Gains Dwarf Static Access Gains

The paper’s back-of-the-envelope welfare calculation yields two striking findings [2:22:08–2:22:41]:

“For China, the dynamic social surplus from innovation is about three times of the static social surplus from the expected patient access, expanded patient access. Second, for the world, these innovative drugs can have international spillovers once they are approved and used in other countries. This international spillover in our estimation is at least as four times as large as the domestic gains from innovation.”

The dynamic consumer surplus alone is approximately twice the static consumer surplus. Yuan cited the example of Tevimbra, a drug developed by a Beijing-based Chinese firm and already approved by the FDA as a first-line treatment for esophageal cancer, extending median survival from 10 to 17 months for US patient.

Policy Significance

The paper speaks to three strands of literature — market size and innovation, firm incentives in R&D, and industrial policy — with its main contribution being the demonstration that effective market size expansion driven by insurance design can be a powerful policy lever for innovation.

As Yuan emphasised in the conclusion [2:56:26–2:56:40]:

“Patient access is important but innovation is at least as important as patient access. Moreover, innovation is not only for one country. It can have international spillover for the world.”

During the discussion, it was noted that the NRDL was not originally motivated by innovation policy — it was a response to public demand for coverage of innovative drugs, primarily cancer therapies. The government later recognised that the expanded market size could stimulate domestic innovation.

For health technology assessment (HTA) practitioners and policymakers, the paper offers a new framework for evaluating healthcare policies: the dynamic efficiency gains from induced innovation may substantially outweigh the static gains from expanded patient access — and a significant share of those gains accrue to patients globally, not just in the innovating country. This aligns with broader discussions on biopharma ecosystem competitiveness and Europe life sciences competitiveness.